Office of AIDS Research (OAR) Brown Bag Seminar Series

 
Data Type Data Value
Date

Monday, September 24, 2018

Time

12:00 - 1:30 PM

Title

”CRISPR/Cas9 Viral and Host Gene Editing for HIV Cure”

Speakers

Kamel Khalili, Ph.D.
Laura H. Carnell Professor and Chair
Department of Neuroscience
Director, Center for Neurovirology
Lewis Katz School of Medicine
Temple University

Tricia H. Burdo, Ph.D.
Associate Professor
Associate Chair of Education
Department of Neuroscience
Lewis Katz School of Medicine
Temple University 

Jennifer Gordon, Ph.D.
Associate Dean, Research
Associate Chair, Research
Associate Professor, Neuroscience/Neurovirology
Lewis Katz School of Medicine
Temple University

Jeffrey M. Jacobson, M.D.
Professor, Medicine
Professor, Neuroscience/Neurovirology
Lewis Katz School of Medicine
Temple University

Hosted by

Mulualem E. Tilahun, DVM, Ph.D.
Health Scientist/AAAS Science & Technology Policy Fellow

Paul A. Sato, M.D., MPH
Coordinator, Research Toward a Cure

Maureen M. Goodenow, Ph.D.
Director
NIH Office of AIDS Research

Location and
Access

OAR Conference Room, 2F100
5601 Fishers Lane, Rockville, MD 20852

Please note: Persons who do not work at the 5601 Fishers Lane building should allow for
an additional 15 minutes to sign-in and pass through security. Visitors will be required to
present photo-identification conforming to REAL ID Act requirements to gain access
to the building.

A public parking garage is located at 5635 Fishers Lane, approximately
one block from 5601. The cost is $4 for the first hour, $6 for the second hour
or $8 a day. The public garage accepts cash only. The nearest Metro station is
Twinbrook, which is less than half a mile away from the building.

DIRECTIONS TO 2F100 CONFERENCE ROOM: After clearing security and
entering through the glass doors, take the first hallway to the right. At the end
of the hallway, take the elevator to the 2nd floor. When exiting the elevator,
proceed to the hallway to the right. Follow that hall again to the right to the end
of the hall. The OAR reception desk will be in front of you and conference room
2F100 to the left of reception. Please call 301-496-0357 if you need assistance
in finding the conference room.  

Speakers Bio:
Kamel Khalili, Ph.D.

Dr. Kamel Khalili received his Ph.D. in Microbiology from the University of Pennsylvania in 1983, and after three years postdoctoral training in the Molecular Virology Laboratory at the National Cancer Institute/NIH in Bethesda (1986), he assumed a faculty position at Thomas Jefferson University (1987-1997), and then Temple University (present). Currently, Drb. Khalili is the Laura H. Carnell Professor and Chair of the Department of Neuroscience, and Director of the Center for Neurovirology at the Lewis Katz School of Medicine at Temple University. In the earlier years of the HIV-1/AIDS pandemic, Dr. Khalili’s work led to several contributions on understanding the neuropathogenesis of AIDS. Recently, he has pioneered the use of the CRISPR gene editing system to eliminate HIV-1 from latently infected cells. He has utilized this system to excise the HIV-1 genome from chromosomes of various cells and organs in several small animal models. This was the first illustration of the permanent elimination of HIV-1 DNA from cell models, ex vivo patient samples, and in vivo animal models.

Jeffrey M. Jacobson, M.D.
Jeffrey M. Jacobson, M.D. has extensive experience in the care and investigative study of patients with HIV and hepatitis virus infections. His particular focus of research has been on the immunology and immunopathogenesis of HIV infection, including vaccine and monoclonal antibody development and gene therapy. Dr. Jacobson received his B.A. and M.D. from Cornell University, and did his internal medicine residence and infectious diseases fellowship training at Mount Sinai Hospital in New York. He is Professor of Medicine, Neuroscience, and Neurovirology and Co-Director of the Center of Translational AIDS Research at the Lewis Katz School of Medicine at Temple University. He has chaired several ACTG committees, including the Immunology Committee and the Translational Research and Drug Development Committee, and has been a member of the Scientific Agenda Steering Committee of the ACTG. Dr. Jacobson co-chaired the Long Acting Drug Task Force in the ACTG, and currently chairs the Microbiome Focus Group and co-chairs the Therapeutic Vaccination Focus Group. He is also a member of the Antiretroviral Treatment Strategies Transformative Science Group and its Monoclonal Antibody Working Group. In addition, he serves on the Executive Committee of the NIH-R24 funded Long/Acting Extended Release Antiretroviral Resource (LEAP) Program.

Tricia H. Burdo, Ph.D.
Dr. Burdo received her Ph.D. in Cell and Molecular Biology from Penn State College of Medicine in 2003, and after four years postdoctoral training at Scripps Research Institute (2007) she became an Assistant Professor (2007-2012) and then Associate Professor (2012-2016) at Boston College. Currently, Dr. Burdo is an Associate Professor and Associate Chair of Education of Neuroscience and at the Lewis Katz School of Medicine at Temple University. Dr. Burdo is a highly productive expert in macrophage biology, HIV and SIV neuropathogenesis and non-human primate models of HIV. Her work has focused on monocyte traffic and pathology in the central and peripheral nervous systems and heart during infection. She has pioneered work on soluble CD163, as a novel plasma biomarker in HIV and was the first to report elevated levels of sCD163 in patients with impaired global deficit scores and in patients with HIV-associated neurocognitive disorders despite virologic suppression. Her work was the first to show sCD163 as a marker of non-calcified vulnerable coronary plaques in HIV-infected patients and a better marker than traditional markers of cardiovascular disease. Her lab has led key studies on the relationship between monocyte activation and myocardial pathology and neuroHIV in the rhesus macaque SIV model of AIDS and in pathological cardiac and brain studies from subjects with HIV. She is an active member of the HIV research community, including a standing member of the National Institute of Health (NIH) NeuroAIDS and End-organ Disease (NAED) study section, member of the advisory committee for the Office of AIDS Research (OAR).

Jennifer Gordon, Ph.D.
Dr. Gordon is an Associate Professor in the Department of Neuroscience and Associate Dean for Research at the Lewis Katz School of Medicine at Temple University. She received her Ph.D. in 1999 from the Department of Pathology at Drexel College of Medicine. Dr. Gordon joined the faculty at Temple in 2001 as an Assistant Professor in the Department of Biology, College of Science and Technology. She then joined the Department of Neuroscience and Center for Neurovirology at the Lewis Katz School of Medicine at Temple University when it was founded in 2006. Her research is focused on basic and translational approaches using small animal models toward understanding neurological disease including neurodevelopmental disorders, neurodegeneration, brain tumors, and demyelination, with a focus on the neurotropic viruses HIV-1 and JC virus. In particular, her interests include studying Pur-alpha, a protein which is essential for brain development, plays a role in neurodegenerative diseases, and interacts with HIV-1 Tat protein as well as cross talk between JC virus (JCV) and HIV-1; BAG3, another protein shown to interact with HIV-1 Tat, which impacts on cellular homeostasis and protein quality control in both brain and in the setting of cardiomyopathy; and other neurotropic viruses and neurotropic viral vectors. Dr. Gordon has been the recipient of numerous NIH grants for her research and has been continuously funded since 2001. She currently serves as Core Leader of the NIH P30 Comprehensive NeuroAIDS Center's Basic Science Core II which focuses on animal models, behavioral testing, and microscopy and neuropathology services. She has extensive experience in immunocompromised mouse models, transgenic and knockout models, biohazardous animal models including HIV-infected humanized mice, and in vivo viral vector delivery studies.

*Please help us spread the word - share this announcement with colleagues.

 

This page last reviewed on September 6, 2018